Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Neuroscience and Neurotech Networking Event

Are you a neuroscientist, neurotech entrepreneur, investor, or healthcare professional looking to expand your network and explore cutting-edge innovations in neuroscience? The PEL Network invites [...]

Go to Top